Literature DB >> 29328556

Coronary artery disease in decompensated patients undergoing liver transplantation evaluation.

Samarth S Patel1, Eiman Nabi1, Luis Guzman2, Antonio Abbate2, Chandra Bhati3, Richard T Stravitz1, Trevor Reichman3, Scott C Matherly1, Carolyn Driscoll1, Hannah Lee1, Velimir A Luketic1, Richard K Sterling1, Arun J Sanyal1, Vaishali Patel1, Marlon Levy3, Mohammad Shadab Siddiqui1.   

Abstract

Coronary artery disease (CAD) is an important contributor to morbidity and mortality in patients undergoing liver transplantation (LT). However, the current literature is limited by sampling bias and nondefinitive assessment of CAD. The current study examines the prevalence of CAD via per protocol coronary angiography and its relationship to etiology of liver disease in patients undergoing liver transplantation evaluation (LTE). Data on 228 patients were prospectively collected who had coronary angiography as part of LTE between 2011 and 2014. Coronary angiography was done in all patients age ≥50 years or with CAD risk factors. CAD was defined as any coronary artery stenosis, whereas stenosis ≥ 70% in distribution of 1 or 3 major coronary arteries was considered as single- or triple-vessel disease. CAD was detected in 36.8% of patients, with the highest prevalence among nonalcoholic steatohepatitis (NASH) patients with cirrhosis (52.8%). Prevalence of single-vessel disease was higher among patients with NASH compared with hepatitis C virus (HCV) and alcoholic cirrhosis (15.1% versus 4.6% versus 6.6%; P = 0.02). Similarly, patients with NASH were more likely to have triple-vessel disease when compared with HCV and alcoholic cirrhosis (9.4% versus 0.9% versus 0%; P = 0.001). While adjusting for traditional risk factors for CAD, only NASH as etiology of liver disease remained significantly associated with CAD. Complications from diagnostic coronary angiography or percutaneous coronary intervention were low (2.6%). In conclusion, patients undergoing LTE have a high prevalence of CAD, which varies widely depending on etiology of liver cirrhosis. The procedural complications from coronary angiography are low. Liver Transplantation 24 333-342 2018 AASLD.
© 2018 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2018        PMID: 29328556     DOI: 10.1002/lt.25012

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  25 in total

Review 1.  CON: Noninvasive Imaging Is the Preferred Strategy for Cardiovascular Risk Stratification in This Patient.

Authors:  Shravan Dave; Abbey Barnard; Michel Mendler
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-02-01

2.  Low yield of routine stress testing in patients awaiting liver transplantation.

Authors:  Cigdem Akincioglu; Saurabh Malhotra
Journal:  J Nucl Cardiol       Date:  2018-08-30       Impact factor: 5.952

3.  Small Dense Low-Density Lipoprotein Cholesterol Predicts Cardiovascular Events in Liver Transplant Recipients.

Authors:  Mohammad Bilal Siddiqui; Tamoore Arshad; Samarth Patel; Emily Lee; Somaya Albhaisi; Arun J Sanyal; R Todd Stravitz; Carolyn Driscoll; Richard K Sterling; Trevor Reichman; Chandra Bhati; Mohammad Shadab Siddiqui
Journal:  Hepatology       Date:  2019-03-29       Impact factor: 17.425

4.  Mind the Gap: Statin Underutilization and Impact on Mortality in Liver Transplant Recipients.

Authors:  Patrick T Campbell; Lisa B VanWagner
Journal:  Liver Transpl       Date:  2019-10       Impact factor: 5.799

Review 5.  Spotlight on Impactful Research: Utilization of Aspirin and Statin in Management of Coronary Artery Disease in Patients With Cirrhosis Undergoing Liver Transplant Evaluation.

Authors:  Leana Frankul; Catherine T Frenette
Journal:  Clin Liver Dis (Hoboken)       Date:  2020-03-26

6.  The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Authors:  Mohammed Eslam; Shiv K Sarin; Vincent Wai-Sun Wong; Jian-Gao Fan; Takumi Kawaguchi; Sang Hoon Ahn; Ming-Hua Zheng; Gamal Shiha; Yusuf Yilmaz; Rino Gani; Shahinul Alam; Yock Young Dan; Jia-Horng Kao; Saeed Hamid; Ian Homer Cua; Wah-Kheong Chan; Diana Payawal; Soek-Siam Tan; Tawesak Tanwandee; Leon A Adams; Manoj Kumar; Masao Omata; Jacob George
Journal:  Hepatol Int       Date:  2020-10-01       Impact factor: 6.047

7.  The relationship between coronary artery disease and cardiovascular events early after liver transplantation.

Authors:  Samarth S Patel; Fei-Pi Lin; Viviana A Rodriguez; Chandra Bhati; Binu V John; Taylor Pence; Mohammad B Siddiqui; Adam P Sima; Antonio Abbate; Trevor Reichman; Mohammad S Siddiqui
Journal:  Liver Int       Date:  2019-03-26       Impact factor: 5.828

8.  A simple clinical calculator for assessing cardiac event risk in liver transplant candidates: The cardiovascular risk in orthotopic liver transplantation score.

Authors:  Lisa B VanWagner
Journal:  Clin Liver Dis (Hoboken)       Date:  2018-07-26

Review 9.  Implications of Nonalcoholic Steatohepatitis as the Cause of End-Stage Liver Disease Before and After Liver Transplant.

Authors:  Anchalia Chandrakumaran; Mohammad Shadab Siddiqui
Journal:  Gastroenterol Clin North Am       Date:  2020-03       Impact factor: 3.806

10.  The Impact of Coronary Artery Disease and Statins on Survival After Liver Transplantation.

Authors:  Samarth S Patel; Viviana A Rodriguez; Mohammad B Siddiqui; Masoud Faridnia; Fei-Pi Lin; Anchalia Chandrakumaran; John Laurenzano; Joseph Clinton; Gurukripa N Kowlgi; Danielle Kirkman; Adam P Sima; Erika Liptrap; Chandra Bhati; Mohammad Shadab Siddiqui
Journal:  Liver Transpl       Date:  2019-08-20       Impact factor: 5.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.